Clinical grand rounds: Atypical hemolytic uremic syndrome

American Journal of Nephrology

Volumn 35, Issue 5, 2012, Pages 394-400

  Hodgkins, Kavita S ^a   Bobrowski, Amy E ^a   Lane, Jerome C ^a   Langman, Craig B ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Acute kidney injury; Alternative complement pathway; Complement factor H; Eculizumab; Kidney transplant; Pediatrics; Thrombotic microangiopathy

Indexed keywords

COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C5; COMPLEMENT COMPONENT C5A; COMPLEMENT FACTOR H; COMPLEMENT FACTOR I; COMPLEMENT MEMBRANE ATTACK COMPLEX; CREATININE; ECULIZUMAB; HEMOGLOBIN; MENINGOCOCCUS VACCINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PENICILLIN G; RAPAMYCIN; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ACUTE KIDNEY FAILURE; BINDING AFFINITY; CARDIOMYOPATHY; CASE REPORT; CATHETER; COMPLEMENT ALTERNATIVE PATHWAY; COMPLEMENT BLOOD LEVEL; CREATININE BLOOD LEVEL; DOWNSTREAM PROCESSING; ECHOGRAPHY; ERYTHROCYTE TRANSFUSION; FEMALE; HEMODIALYSIS; HEMOGLOBIN BLOOD LEVEL; HEMOLYTIC UREMIC SYNDROME; HUMAN; HUMAN TISSUE; HYPERTENSION; INFANT; KIDNEY BIOPSY; KIDNEY FAILURE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LYMPHOCYTIC INFILTRATION; NAUSEA AND VOMITING; NUTRITIONAL STATUS; OLIGURIA; PERITONEAL DIALYSIS; PERITONITIS; PLASMAPHERESIS; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN CLEAVAGE; RECURRENT DISEASE; RENAL GRAFT DYSFUNCTION; REVIEW; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; ULTRASOUND; UREA NITROGEN BLOOD LEVEL; UREMIA;

ANTIBODIES, MONOCLONAL, HUMANIZED; COMPLEMENT MEMBRANE ATTACK COMPLEX; FEMALE; HEMOLYTIC-UREMIC SYNDROME; HUMANS; INFANT; KIDNEY TRANSPLANTATION; TREATMENT OUTCOME;

EID: 84861618238     PISSN: 02508095     EISSN: 14219670     Source Type: Journal    
DOI: 10.1159/000337954     Document Type: Review

References (36)

1. Kavanagh D, Richards A, Atkinson J: Complement regulatory genes and hemolytic ure-mic syndromes. Annu Rev Med 2008; 59: 293-309. (Pubitemid 351287939)
2. FDA News Release Sept 23, 2011. http://www.fda.gov/NewsEvents/Newsroom/ PressAnnouncements/ucm272990.htm.
3. Noris M, Remuzzi G: Hemolytic uremic syndrome. J Am Soc Nephrol 2005; 16:1035-1050. (Pubitemid 41710314)
4. Moake JL: Thrombotic microangiopathies. N Engl J Med 2002; 347: 589-590.
5. Coppo P, Veyradier A: Thrombotic micro-angiopathies: towards a pathophysiology-based classification. Cardiovasc Hematol Disord Drug Ta rgets 2009; 9: 36-50.
6. Noris M, Remuzzi G: Atypical hemolytic-uremic syndrome. N Engl J Med 2009; 361: 1676-1687.
7. Lapeyraque AL, Malina M, Frémeaux-Bac-chi V, Boppel T, Kirschfink M, Oualha M, Proulx F, Clermont MJ, Le Deist F, Niaudet P, Schaefer F: Eculizumab in severe Shiga toxin-associated HUS. N Engl J Med 2011;364:2561-2563.
8. Stahl A, Sartz L, Karpman D: Complement activation on platelet-leukocyte complexes and microparticles in enterohemorrhagic Escherichia coli-induced hemolytic uremic syndrome. Blood 2011; 117:5503-5513.
9. Kavanagh D, Goodship THJ: Atypical hemolytic uremic syndrome. Curr Opin Hematol 2010; 17:432-438.
10. Dmytrijuk A, Robie-Suh K, Cohen MH, Rieves D, Weiss K, Pazdur R: FDA report: eculizumab (Soliris®) for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Oncologist 2008; 13: 993-1000.
11. De S, Waters AM, Segal AO, Trautmann A, Harvey EA, Licht C: Severe atypical HUS caused by CFH S1191L-case presentation and review of treatment options. Pediatr Nephrol 2010; 25:97-104.
12. Nürnberger J, Philipp T, Witzke O, Saez AO, Vester U, Baba HA, Kribben A, Zimmer-hackl LB, Janecke AR, Nagel M, Kirschfink M: Eculizumab for atypical hemolytic-uremic syndrome. N Engl J Med 2009; 360:542-544.
13. Gruppo RA, Rother RP: Eculizumab for congenital atypical hemolytic-uremic syndrome. N Engl J Med 2009; 360:544-546.
14. Mache CJ, Acham-Roschitz B, Frémeaux-Bacchi V, Kirschfink M, Zipfel PF, Roedl S, Vester U, Ring E: Complement inhibitor ecu-lizumab in atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol 2009; 4: 1312-1316.
15. Châtelet V, Frémeaux-Bacchi V, Lobbedez T, Ficheux M, Hurault de Ligney B: Safety and long-term efficacy of eculizumab in a renal transplant patient with recurrent atypical hemolytic-uremic syndrome. Am J Transplant 2009: 9; 2644-2645.
16. Châtelet V, Lobbedez T, Frémeaux-Bacchi V, Ficheux M, Ryckelynck JP, Hurault de Ligney B: Eculizumab: safety and efficacy after 17 months of treatment in a renal transplant patient with recurrent atypical hemolytic-ure-mic syndrome: case report. Transplant Proc 2010; 42:4353-4355.
17. Davin JC, Gracchi V, Bouts A, Groothoff J, Strain L, Goodship T: Maintenance of kidney function following treatment with eculi-zumab and discontinuation of plasma exchange after a third kidney transplant for atypical hemolytic uremic syndrome associated with a CFH mutation. Am J Kidney Dis 2010; 55:708-711.
18. Larrea C, Cofan F, Oppenheimer F, Campis-tol JM, Escolar G, Lozano M: Efficacy of ecu-lizumab in the treatment of recurrent atypical hemolytic-uremic syndrome after renal transplantation. Transplantation 2010; 85: 976-977.
19. Prescott HC, Wu HM, Cataland SR, Baiocchi RA: Eculizumab therapy in an adult with plasma exchange-refractory atypical hemo-lytic uremic syndrome. Am J Hematol 2010; 5: 976-977.
20. Al-Akash SI, Almond PS, Savell VH, Gha-raybeh SI, Hogue C: Eculizumab induces long-term remission in recurrent post-transplant HUS associated with C3 gene mutation. Pediatr Nephrol 2011; 26: 613-619.
21. Lapeyraque AL, Frémeaux-Bacchi V, Robi-taille P: Efficacy of eculizumab in a patient with factor-H-associated atypical hemolytic uremic syndrome. Pediatr Nephrol 2011; 26: 621-624.
22. Tschumi S, Gugger M, Bucher BS, Riedl M, Simonetti GD: Eculizumab in atypical he-molytic uremic syndrome: long-term clinical course and histological findings. Pediatr Nephrol 2011; 26: 2085-2088.
23. Ohanian M, Cable C, Halka K: Eculizumab safely reverses neurologic impairment and elimi nates need for dia lysis i n severe at y pic a l hemolytic uremic syndrome. Clin Pharmacol 2011; 3:5-12.
24. Ohanian M, Cable C, Halka K: Reduced dose maintenance eculizumab in atypical hemo-lytic uremic syndrome (aHUS): an update on a previous case report. Clin Pharmacol 2011; 3:45-50.
25. Legault DJ, Boelkins MR: Successful treatment of aHUS recurrence and arrest of plasma exchange resistant TMA post-renal transplantation with terminal complement inhibitor eculizumab. Annual Meeting and Exposition of 51st American Society of He-matology, New Orleans 2009.
26. Fremont OT, Gordon CA, Hand MM: Eculi-zumab treatment for aHUS in a child with positive family history. Renal Week 2009. 42nd Annual Meeting of the American Society of Nephrology, San Diego 2009.
27. Häffner K, Hofer J, Zimmerhackl LB, Pohl M: Effective eculizumab therapy of familiar atypical HUS in a 4-year-old patient. 2nd International Conference HUS-MPGN-PNH: Current Diagnosis and Therapy of Throm-botic Microangiopathies: Hemolytic Uremic Syndrome, Membranoproliferative Glomer-ulonephritis and Paroxysmal Nocturnal He-moglobinuria, Innsbruck 2010.
28. Loos S, Lehnhardt A, van Husenl M, Klaas-sen I, Möller K, Kemper MJ: Rescue therapy with eculizumab fails to prevent graft loss in a renal transplant patient with factor I mutation: chronic rejection or recurrence? 2nd International Conference HUS-MP-GN-PNH: Current Diagnosis and Therapy of Thrombotic Microangiopathies: Hemo-lytic Uremic Syndrome, Membranoprolif-erative Glomerulonephritis and Paroxysmal Nocturnal Hemoglobinuria, Innsbruck 2010.
29. Aguirre M, Arrizabalaga B, Abarrategui C, Morteruel E, López-Trascasa M, Areses R, Quintela MJ, Ariceta G: Eculizumab phar-macokinetics and efficacy in a newborn with aHUS: an option in no-candidates to plas-maexchange. 44th Annual Scientific Meeting of the European Society for Paediatric Nephrology, Cavtat-Dubrovnik 2011.
30. Malina M, Gulati A, Majid MA, Bagga A, Schafer F: Peripheral gangrenes in children with atypical hemolytic uremic syndrome. 44th Annual Scientific Meeting of the European Society for Paediatric Nephrology, Cavtat-Dubrovnik 2011.
31. Zimmerhackl LB, Hofer J, Cortina G, Mark W, Würzner R, Jungraithmayr TC: Prophylactic eculizumab after renal transplantation in atypical hemolytic-uremic syndrome. N Engl J Med 2010; 362:1746-1748.
32. Weitz M, Amon O, Bassler D, Koenigsrainer A, Nadalin S: Prophylactic eculizumab prior to kidney transplantation for atypical hemo-lytic uremic syndrome. Pediatr Nephrol 2011; 26: 1325-1329.
33. Nester C, Stewart Z, Myers D, Jetton J, Nair R, Reed A, Thomas C, Smith R, Brophy P: Preemptive eculizumab and plasmapheresis for renal transplant in atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol 2011; 6:14 88-1494
34. FDA Drug Product Label for Soliris (BLA) 125166, approved Sept 23, 2011. http://www.accessdata.fda.gov/drugsatfda-docs/label/2011/125166s172lbl.pdf.
35. Zuber J, Le Quintrec M, Sberro-Soussan R, Loirat C, Frémeaux- Bacchi V, Legendre C: New insights into postrenal transplant he-molytic uremic syndrome. Nat Rev Nephrol 2011; 7: 23-35.
36. Saland JM, Ruggenenti P, Remuzzi G: Liver-kidney transplantation to cure atypical he-molytic uremic syndrome. J Am Soc Nephrol 2009; 20:940-949.